The basal-like tumours are usually ER, PR and HER2-negative and are also associated with germ-line BRCA1 mutations, one of the most important forms of the hereditary breast cancer16. HER2-positive breast cancers are characterised by high expression of HER2, usually as a result of amplification of the 17q12q21 locus that contains the HER2 gene. research and treatment, it is still one of the leading causes of cancer-related deaths among women and a major health problem in the developed world. Over 1 . 7 million women are diagnosed with breast cancer, worldwide, representing about 12% of all new cancer cases and about 25% of all cancers in women and over half a million women die from the disease each year1. Although the overall breast cancer-related mortality rate has slightly declined, the American Cancer Society projects more than 246, 660 new cases of breast cancer with over 40, 450 deaths of American women each year2. Additionally , while many patients are treated successfully, one third of breast cancer patients experience cancer metastasis or recurrence in their lifetime3. Many of the differences in disease progression are because breast cancer is not a single disease but rather a heterogeneous group of diseases with distinct pathological, morphological, and molecular features with clinical outcomes depending on tumour characteristics. The further molecular characterization of each breast cancer subtype would enable us to develop subtype specific treatments with resulting increases in breast cancer survival rates. Breast cancer is caused by several factors including an accumulation of chromosomal aberrations of either genetic or environmental origin4. These abnormalities range from DNA point mutations to chromosomal defects such as chromosomal instability, copy number variation, translocation, and epigenetic alteration4. In recent decades genomic and transcriptomic technologies have led to the identification and characterization of several breast cancer-related genes. These include BRCA15, ErBB26(also known as HER2), ESR17(also known as ER) and protein kinases, such as ATM, 8that acquire driver mutations in certain human breast cancers9. The advent of cDNA microarray technology and subsequently RNAseq has enabled us to look at global patterns of gene expression in breast cancer cells, which Bevenopran can be classified according to distinct molecular characteristics10. However , gene expression patterns do not necessarily reflect proteome pattern of diseased cells. Cellular protein regulation LPL antibody is a dynamic process controlled by translation, post-translational modifications, protein stability and protein degradation11. Characterisation of proteomes is now possible using MS-based quantitative proteomics, which is capable of sensitive protein identification and quantitation. We can examine the cancer proteomes that are responsible for functional cellular changes with high accuracy and supplement our understanding of genomic and transcriptomic changes to achieve a more sophisticated understanding of the molecular causes of different breast cancers11. Proteomics technologies allow us to quantitatively examine large numbers of proteins in complex protein mixtures and to map post-translational protein modifications under different circumstances. Considering the heterogeneity and complexity of carcinogenesis, proteomics technologies provide suitable tools for investigating the complex network Bevenopran of protein interactions that cannot be examined using the classical one-gene-one-protein approach. Therefore , proteomics has emerged as an integral part of modern biomedicine. For example , proteomics tools have been used for both cancer diagnosis and therapy selection as well as for researching the underlying mechanisms of disease pathogenesis and progression1214. Specifically, one recent proteomic-based breast cancer study uncovered clinically distinct protein signatures for different histologically graded tumors12. Another study developed a triple-negative breast cancer-specific protein profile13and a study by Tyanovaet al. characterised functional differences between different breast cancer subtypes14. In this review, we present a comparative overview of the different labelled and label free quantitative proteomics techniques used to address various biological parameters. We will examine their effectiveness in elucidating the protein signatures in breast cancer subtypes and especially triple-negative breast cancer, and their overall impact on molecular breast cancer research. == Non-mass spectrometry-based proteomic platforms in cancer research == Proteomic studies are varied, Bevenopran but can be categorized based on whether or not MS is used in the analysis pipeline. While most MS-based proteomic studies allow us to examine protein mixtures without prior biological knowledge of the protein content10, prior knowledge of the targeted protein is a prerequisite for non-MS based approaches. For instance, non-MS techniques such as Western blotting, enzyme-linked-immunosorbent assay (ELISA), immunohistochemistry (IHC), immunocytochemistry (ICC), and recently protein microarray (PMA) and tissue microarray.
The basal-like tumours are usually ER, PR and HER2-negative and are also associated with germ-line BRCA1 mutations, one of the most important forms of the hereditary breast cancer16